Emily Bodnar
Stock Analyst at H.C. Wainwright
(4.19)
# 1,564
Out of 4,693 analysts
683
Total ratings
40%
Success rate
7.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Bodnar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TGTX TG Therapeutics | Maintained: Buy | $78 | $56.09 | +39.06% | 14 | Sep 1, 2026 | |
| ODTX Odyssey Therapeutics | Initiated Coverage: Buy | $44 | $24.50 | +79.59% | 1 | Aug 27, 2026 | |
| JSPR Jasper Therapeutics | Reiterated: Buy | $20 | $0.6976 | +2,766.97% | 22 | Aug 18, 2026 | |
| IMNN Imunon | Reiterated: Buy | $25 | $1.60 | +1,462.50% | 27 | Aug 14, 2026 | |
| INKT MiNK Therapeutics | Reiterated: Buy | $35 | $10.95 | +219.63% | 27 | Aug 14, 2026 | |
| GNLX Genelux | Maintained: Buy | $31 | $2.60 | +1,092.31% | 16 | Aug 14, 2026 | |
| NXTC NextCure | Reiterated: Buy | $20 | $6.80 | +194.12% | 16 | Aug 13, 2026 | |
| ACRV Acrivon Therapeutics | Maintained: Buy | $19 | $2.07 | +817.87% | 25 | Aug 13, 2026 | |
| TRAX First Tracks Biotherapeutics | Rated: Buy | $44 → $57 | $41.17 | +38.45% | 5 | Aug 13, 2026 | |
| AGEN Agenus | Rated: Buy | $30 → $25 | $7.99 | +212.89% | 41 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $2.31 | +332.90% | 8 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $16 → $14 | $2.70 | +418.52% | 31 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $38 → $36 | $10.56 | +240.91% | 47 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $7 | $3.83 | +82.77% | 27 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $52 → $60 | $44.02 | +36.30% | 4 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $30 → $17 | $1.66 | +924.10% | 20 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $45 → $42 | $31.95 | +31.46% | 11 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 | $11.28 | +210.28% | 10 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 | $29.71 | +51.46% | 21 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $3.70 | +170.27% | 12 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $0.3643 | +1,272.50% | 39 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $1.48 | - | 14 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $52 → $55 | $34.21 | +60.77% | 24 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $46 → $52 | $17.38 | +199.19% | 45 | Jul 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.42 | - | 27 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $0.34 | +3,429.41% | 5 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $55 → $66 | $55.28 | +19.39% | 20 | Mar 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $5.42 | +232.10% | 1 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.000001 | - | 24 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $55.57 | $5.05 | +1,000.32% | 34 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $160 | $3.26 | +4,807.98% | 32 | Sep 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.06 | n/a | 22 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8 | $2.36 | n/a | 5 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.02 | n/a | 6 | May 22, 2024 |
TG Therapeutics
Sep 1, 2026
Maintained: Buy
Price Target: $78
Current: $56.09
Upside: +39.06%
Odyssey Therapeutics
Aug 27, 2026
Initiated Coverage: Buy
Price Target: $44
Current: $24.50
Upside: +79.59%
Jasper Therapeutics
Aug 18, 2026
Reiterated: Buy
Price Target: $20
Current: $0.6976
Upside: +2,766.97%
Imunon
Aug 14, 2026
Reiterated: Buy
Price Target: $25
Current: $1.60
Upside: +1,462.50%
MiNK Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $35
Current: $10.95
Upside: +219.63%
Genelux
Aug 14, 2026
Maintained: Buy
Price Target: $31
Current: $2.60
Upside: +1,092.31%
NextCure
Aug 13, 2026
Reiterated: Buy
Price Target: $20
Current: $6.80
Upside: +194.12%
Acrivon Therapeutics
Aug 13, 2026
Maintained: Buy
Price Target: $19
Current: $2.07
Upside: +817.87%
First Tracks Biotherapeutics
Aug 13, 2026
Rated: Buy
Price Target: $44 → $57
Current: $41.17
Upside: +38.45%
Agenus
Aug 11, 2026
Rated: Buy
Price Target: $30 → $25
Current: $7.99
Upside: +212.89%
Aug 11, 2026
Maintained: Buy
Price Target: $10
Current: $2.31
Upside: +332.90%
Aug 11, 2026
Rated: Buy
Price Target: $16 → $14
Current: $2.70
Upside: +418.52%
Aug 11, 2026
Reiterated: Buy
Price Target: $38 → $36
Current: $10.56
Upside: +240.91%
Aug 11, 2026
Maintained: Buy
Price Target: $7
Current: $3.83
Upside: +82.77%
Aug 11, 2026
Rated: Buy
Price Target: $52 → $60
Current: $44.02
Upside: +36.30%
Aug 10, 2026
Rated: Buy
Price Target: $30 → $17
Current: $1.66
Upside: +924.10%
Aug 7, 2026
Rated: Buy
Price Target: $45 → $42
Current: $31.95
Upside: +31.46%
Aug 7, 2026
Maintained: Buy
Price Target: $35
Current: $11.28
Upside: +210.28%
Aug 6, 2026
Maintained: Buy
Price Target: $45
Current: $29.71
Upside: +51.46%
Aug 6, 2026
Maintained: Buy
Price Target: $10
Current: $3.70
Upside: +170.27%
Aug 6, 2026
Maintained: Buy
Price Target: $5
Current: $0.3643
Upside: +1,272.50%
Aug 5, 2026
Maintained: Hold
Price Target: n/a
Current: $1.48
Upside: -
Jul 30, 2026
Maintained: Buy
Price Target: $52 → $55
Current: $34.21
Upside: +60.77%
Jul 24, 2026
Rated: Buy
Price Target: $46 → $52
Current: $17.38
Upside: +199.19%
Jun 15, 2026
Rated: Hold
Price Target: n/a
Current: $2.42
Upside: -
May 15, 2026
Maintained: Buy
Price Target: $12
Current: $0.34
Upside: +3,429.41%
Mar 30, 2026
Maintained: Buy
Price Target: $55 → $66
Current: $55.28
Upside: +19.39%
Feb 23, 2026
Initiated Coverage: Buy
Price Target: $18
Current: $5.42
Upside: +232.10%
Nov 17, 2025
Maintained: Hold
Price Target: n/a
Current: $0.000001
Upside: -
Oct 13, 2025
Maintained: Buy
Price Target: $55.57
Current: $5.05
Upside: +1,000.32%
Sep 26, 2025
Maintained: Buy
Price Target: $160
Current: $3.26
Upside: +4,807.98%
Apr 29, 2025
Rated: Hold
Price Target: n/a
Current: $2.06
Upside: n/a
Mar 31, 2025
Maintained: Buy
Price Target: $8
Current: $2.36
Upside: n/a
May 22, 2024
Rated: Hold
Price Target: n/a
Current: $2.02
Upside: n/a